Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 16, 2026 in Vistagen Lawsuit - VTGN

Levi & Korsinsky, LLP has put out a reminder for investors in Vistagen Therapeutics, Inc. (NASDAQ: VTGN) regarding the upcoming lead plaintiff deadline for a class action securities lawsuit. Shareholders who experienced losses due to alleged securities fraud between April 1, 2024, and December 16, 2025, must act by March 16, 2026, to be considered for lead plaintiff status. The essence of the lawsuit revolves around claims that Vistagen and its executives provided misleading statements that resulted in significant financial losses for investors.

The complaint addresses the company’s communications surrounding its Phase 3 PALISADE-3 trial for fasedienol, an investigational treatment for social anxiety disorder. According to the allegations, Vistagen consistently portrayed its trial results in an overly optimistic light while concealing material adverse facts. A crucial turning point occurred on December 17, 2025, when Vistagen announced that the results of the PALISADE-3 trial failed to meet its primary endpoint, revealing that there was no meaningful difference between fasedienol and a placebo. Following this announcement, Vistagen’s stock price plummeted from $4.36 per share to $0.86, reflecting a staggering decline of over 80%.

Investors who suffered losses during the specified period can participate in the class action without needing to incur costs upfront. Levi & Korsinsky underscores its extensive expertise and track record in securities litigation, positioning itself as a reliable advocate for aggrieved shareholders. A dedicated team is prepared to navigate the complexities of the case, emphasizing no financial burden for class members. Interested shareholders are urged to reach out for guidance and further information regarding their potential involvement.

In light of the recent developments concerning Vistagen Therapeutics, Inc. (NASDAQ: VTGN), shareholders facing significant losses may want to consider their options as the company navigates a class action lawsuit initiated by Levi & Korsinsky. The lawsuit arises from allegations of securities fraud stemming from misleading actions related to the Phase 3 PALISADE-3 trial of their investigational drug, fasedienol. Following the trial's unimpressive results, which were disclosed on December 17, 2025, Vistagen's stock plummeted from $4.36 to $0.86 per share—an alarming decline of more than 80%.

For shareholders impacted during the defined period (April 1, 2024, to December 16, 2025), the deadline to request appointment as a lead plaintiff is March 16, 2026. It's crucial for affected investors to weigh the benefits of potentially joining the lawsuit, as participating does not require serving as a lead plaintiff, and no costs are incurred to take part. This could present an avenue to recover losses incurred due to the alleged misrepresentations and lack of transparency.

Investors should keep a watchful eye on the broader implications of this case for Vistagen’s future. The company’s ability to rebound from this setback may hinge on its next steps, including potential strategies for addressing investor concerns and revitalizing confidence in its drug development pipeline.

As always, investors are advised to conduct thorough research and consider the risks associated with litigation outcomes while keeping in mind their investment horizon and risk tolerance. It may also be wise to consult with a financial advisor to navigate the complexities of this volatile situation.